NeoGenomics, Inc (NEO)

Etorro trading 970x250
NeoGenomics, Inc (NEO) Logo

About NeoGenomics, Inc

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited; and has collaboration with Elevation Oncology to expand genomic testing for NRG1 fusions across solid tumors. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Address: 12701 Commonwealth Drive, Fort Myers, FL, United States, 33913

NeoGenomics, Inc News and around…

Latest news about NeoGenomics, Inc (NEO) common stock and company :

The Implications Behind Genetron Health's Latest Earnings Report
03 Dec, 2021 FinancialContent

Image provided by Mentor Finance Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its ...

NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
30 Nov, 2021 FinancialContent
Genetron Health Reports Third Quarter 2021 Unaudited Financial Results
30 Nov, 2021 Yahoo! Finance

BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited preliminary financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Financials: Recorded total revenue of RMB 152.5 million

NASDAQ: NEO Shareholder Notice: Investigation over Potential Wrongdoing at NeoGenomics, Inc.
29 Nov, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 11/29/2021 -- An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced.

The Math Shows IHF Can Go To $316
29 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Notable Tuesday Option Activity: NEO, INTU, CPRT
23 Nov, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NeoGenomics Inc (NEO), where a total volume of 4,591 contracts has been traded thus far today, a contract volume which is representative of approximately 459,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 54.7% of NEO's average daily trading volume over the past month, of 839,530 shares..

Is NeoGenomics (NEO) A Smart Long-Term Buy?
23 Nov, 2021 Yahoo! Finance

Artisan Partners, a high value-added investment management firm, published its ‘Artisan Mid Cap Fund’ third quarter 2021 investor letter – a copy of which can be downloaded here. A return of 3.06% was recorded by its Investor Class: ARTMX, 3.11% by its Advisor Class: APDMX, and 3.12% by its Institutional Class: APHMX, in the third quarter […]

NASDAQ:NEO Investor Notice: Investigation over Possible Securities Laws Violations by NeoGenomics, Inc.
10 Nov, 2021 FinancialContent

San Diego, CA -- (SBWIRE) -- 11/10/2021 -- NeoGenomics, Inc. is under investigation concerning possible violations of securities laws in connection with certain financial statements.

NeoGenomics Appoints Dave Daly to Its Board of Directors
10 Nov, 2021 FinancialContent
Genetron Health Establishes Strategic Partnership with NeoGenomics to Drive Global Oncology Drug Research and Development
08 Nov, 2021 Yahoo! Finance

BEIJING, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has entered into a strategic partnership with NeoGenomics, Inc. (NASDAQ: NEO), a company that specializes in cancer genetic testing and information services. Genetron Health

NeoGenomics, inc (NEO) Q3 2021 Earnings Call Transcript
06 Nov, 2021 FinancialContent

NEO earnings call for the period ending September 30, 2021.

Where NeoGenomics Stands With Analysts
05 Nov, 2021 FinancialContent

Over the past 3 months, 4 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically ...

81 Biggest Movers From Yesterday
05 Nov, 2021 FinancialContent

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on ...

55 Stocks Moving In Thursday's Mid-Day Session
04 Nov, 2021 FinancialContent

Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. ...

NeoGenomics (NEO) Reports Q3 Loss, Lags Revenue Estimates
04 Nov, 2021 Yahoo! Finance

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -1.67%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

A bargain you can’t ignore: Small-cap stocks are trading at their second-lowest discount in 20 years
04 Nov, 2021 FinancialContent

Small-caps as a group appear set for a much better 2022 than large-cap equities.

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
04 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral ...

Recap: NeoGenomics Q3 Earnings
04 Nov, 2021 FinancialContent

NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what ...

NeoGenomics Reports Revenue of $121 Million in the Third Quarter
04 Nov, 2021 FinancialContent
NeoGenomics Announces Leadership Team Transition
04 Nov, 2021 FinancialContent
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct, 2021 FinancialContent

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly ...

Analysts Estimate NeoGenomics (NEO) to Report a Decline in Earnings: What to Look Out for
28 Oct, 2021 Yahoo! Finance

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied PSCH Analyst Target Price: $227
25 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap Health Care ETF (PSCH), we found that the implied analyst target price for the ETF based upon its underlying holdings is $226.73 per unit.

NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
19 Oct, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct, 2021 FinancialContent

Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX:REI) was changed from Neutral to Buy. For the second ...

NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
13 Oct, 2021 FinancialContent
NeoGenomics Announces Board of Directors' Transition
12 Oct, 2021 FinancialContent
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
04 Oct, 2021 FinancialContent

Guardant Health Inc(NASDAQ: GH) hasdecided not to pursue a potential acquisitionofNeoGenomics ...

Friday's ETF with Unusual Volume: IJT
01 Oct, 2021 FinancialContent

The iShares S&P Small-Cap 600 Growth ETF is seeing unusually high volume in afternoon trading Friday, with over 1.0 million shares traded versus three month average volume of about 108,000. Shares of IJT were up about 1.7% on the day.

Why Guardant Health Is Down More Than 14% Friday
01 Oct, 2021 FinancialContent

Investors aren't fans of an acquisition the diagnostics company is rumored to be considering.

NeoGenomics, Inc (NEO) is a NASDAQ Common Stock listed in , ,

970x250